Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
Novartis hopes to repeat the risky regulatory path of its competitor Travere Therapeutics after its phase 3 trial of its IgAN drug missed statistical significance on a kidney function endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results